Clinical Trials Logo

Clinical Trial Summary

The goal of this non-interventional study is to investigate the efficacy and tolerability of an Ectoin containing Rhinosinusitis Nasal Spray (SNS01). Within the study, SNS01 will be used either alone as monotherapy or as concomitant therapy in addition to the use of a Xylometazoline-containing decongestant nasal spray. A control group will use a Xylometazoline-containing decongestant nasal spray as monotherapy.

It will be investigated if the dose of the used decongestant nasal spray might be reduced, the development of the disease might be positively influenced and/or the potentially occurring side effects (e.g. dryness of the nasal mucosa, sneezing) might be alleviated by using the Ectoin containing Rhinosinusitis Nasal Spray as concomitant therapy.


Clinical Trial Description

The current non-interventional study aims to investigate the efficacy and tolerability of Ectoin containing Rhinosinusitis Nasal Spray (SNS01) in patients with acute rhinosinusitis. Patients can chose one of three treatment options: a) Ectoin containing Rhinosinusitis Nasal Spray (SNS01), b) decongestant Xylometazoline-containing nasal spray or c) Ectoin containing Rhinosinusitis Nasal Spray (SNS01) and a decongestant Xylometazoline-containing nasal spray.

Efficacy will be studied by documentation of the following symptoms:

- oedema, redness (assessed by rhinoscopy)

- nasal obstruction, nasal secretion, headache/face pain, loss of sense of smell/taste

- sore throat, cough

In parallel, participating patients will document their symptoms and the their quality of life over the entire study duration in patient diaries.

Patients of both genders aged 6 years and above can take part in the study if diagnosed with acute viral rhinosinusitis. The assignment of a patient to a particular treatment is not decided in advance but falls within current practice, and is clearly separated from the decision to include the patient into the study.

Study therapy will be applied in accordance with the respective instructions for use.

Study duration is 7-14 days, depending on the improvement of symptoms. At the end of the study, both the investigators and the patients are asked to judge the efficacy and tolerability of the treatments. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03693976
Study type Observational
Source Bitop AG
Contact
Status Completed
Phase
Start date October 1, 2018
Completion date April 15, 2019

See also
  Status Clinical Trial Phase
Completed NCT04131686 - NAC Inhalation in the Treatment Of Symptomatic acuTe rhinosinUSitis
Not yet recruiting NCT03517215 - The Development and Testing of a Scaling Strategy for a Community-Based Primary Care Antimicrobial Stewardship Program N/A
Completed NCT05639959 - Efficacy and Safety of New Mometasone Furoate Nasal Spray Formulation in Acute Rhinosinusitis Patients: A Randomized Clinical Trial
Completed NCT00377403 - Treatment of Acute Sinusitis Phase 4
Completed NCT03480100 - Non-interventional Study of Ectoin Nasal Douche (END01) in Patients With Acute Viral Rhinosinusitis
Completed NCT02296814 - Efficacy and Safety of Sinusitis Hevert SL Tablets Compared to Placebo in Adult Patients With Acute, Uncomplicated Rhinosinusitis Phase 4
Completed NCT01553110 - An Observational Study to Evaluate The Relationship of Nasal Mucus Properties and Symptoms
Completed NCT01691677 - beCLomethasone Efficacy in Acute Rhinosinusitis - CLEAR Study Phase 3
Completed NCT01146860 - Efficacy and Safety of a Herbal Medicinal Product (Dry Extract BNO 1016) in Patients With Acute Rhinosinusitis Phase 3
Completed NCT00750750 - Effectiveness and Safety of Once or Twice Daily Mometasone Nasal Spray Versus Amoxicillin Versus Placebo for Treatment of Acute Rhinosinusitis (Study P02683) Phase 2
Completed NCT00751075 - Effectiveness and Safety of Once or Twice Daily Mometasone Nasal Spray Versus Amoxicillin Versus Placebo for Treatment of Acute Rhinosinusitis (Phase 3 Study)(Study P02692) Phase 3